In a report issued on August 3, Ben Hendrix from RBC Capital maintained a Buy rating on CVS Health (CVS – Research Report), with a price target of $119.00. The company’s shares closed last Friday at $102.26.
According to TipRanks.com, Hendrix is a 2-star analyst with an average return of -0.5% and a 53.6% success rate. Hendrix covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, Brookdale Senior Living, and Acadia Healthcare.
CVS Health has an analyst consensus of Moderate Buy, with a price target consensus of $119.09, a 17.3% upside from current levels. In a report released yesterday, Jefferies also maintained a Buy rating on the stock with a $130.00 price target.
Based on CVS Health’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $76.83 billion and net profit of $2.31 billion. In comparison, last year the company earned revenue of $72.62 billion and had a net profit of $2.78 billion.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Headquartered in Rhode Island and founded in 1963, CVS Health Corp. is a healthcare company in the U.S. that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; Aetna, a health insurance provider, among many other brands.
Read More on CVS: